Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/362877


New Approaches to the Treatment of Non-Hodgkin's Lymphoma


Description: Non-Hodgkin’s lymphoma, consisting of 29 different malignancies of the lymphatic system, is a devastating disease: although treatable, only a small percentage of these cancers are curable, and median survival of aggressive NHLs is poor. While treatment has greatly improved since the introduction of Genentech’s Rituxan in 1997, considerable unmet treatment needs remain, spurring significant development in NHL therapies.

Get the Answers You Need to Shape Your Strategy
Genentech’s Rituxan has generated strong growth in the NHL market since its launch, although Rituxan’s market penetration may have peaked. What factors will drive future growth in the NHL market? Where do opportunities lie in the treatment of NHL? How will emerging agents stack up against Rituxan?

With the launch of new agents, cost will become a driving factor in NHL treatment. Which emerging therapies or drug classes will command the highest prices in the NHL market? How will third-party payers respond to the arrival of potent but potentially expensive NHL therapies?

As many as 20 new therapies are in development for the treatment of NHL. Where will new therapies that arrive on the market fit alongside existing treatment regimens for NHL? What types of NHL will benefit most from new therapies? How will these agents be positioned in the market? What present agents, if any, will face competition?

Scope
Overview of non-Hodgkin’s lymphoma: disease characteristics, risk factors, classification and staging, and diagnosis and prevalence.
Lymphomas covered: follicular lymphoma, B-cell lymphomas, T-cell lymphomas, mantle cell lymphoma.
Current therapies: overview of agents currently in use to treat NHL.
Emerging therapies: a review of leading agents in development for NHL.
Drug classes covered: novel chemotherapy agents, combination therapies, vaccines, monoclonal antibodies, radioimmunotherapies.
Market outlook: our projections for how emerging agents could alter the NHL landscape.


Contents: Executive Summary 3
Strategic Considerations 3
Stakeholder Implications 3

Introduction 4
Overview of Non-Hodgkin’s Lymphoma 4
Disease Characteristics and Risk Factors 4
Disease Classification, Staging, and Grade 6
Diagnosis and Prevalent and Incident Cases 8
Current Therapies 9
Emerging Therapies 13

Novel Chemotherapy Agents 13
Hana Bioscience’s Marquibo 13
Cephalon’s Treanda 13
Agents for Use in Combination with Rituxan 15

Vaccines 15
Genentech/Roche/Chugai’s Avastin 17
Immunomedics’ Epratuzumab 17
Biogen Idec’s Galiximab 18
Celgene’s Revlimid 18
Agents in Development for T-Cell Lymphomas 18

Gloucester Pharmaceuticals’ Romidepsin 18
Seattle Genetics’ SGN-30 19
Agents in Development for Mantle Cell Lymphoma 19
Wyeth’s Temsirolimus 19
Genta’s Genasense 19
Millennium Pharmaceuticals’ Velcade 19
Agents in Development for Relapsed or Refractory NHL 20

Genmab’s HuMax-CD20 20
Eli Lilly’s Enzastaurin 20
Other Agents in Development 21
Human Genome Sciences/GlaxoSmithKline’s Mapatumumab 21

Outlook for the NHL Market 21

Tables:
1. Descriptions of Common Types of Non-Hodgkin’s Lymphomas 5
2. The WHO Classification System for Non-Hodgkin’s Lymphoma 7
3. Lymphoma Staging System: Ann Arbor Classification 8
4. Current Therapy Regimens for Non-Hodgkin’s Lymphoma 10
5. Select Agents in Development for Non-Hodgkin’s Lymphoma 14

Figures:
1. Prevalent and Incident Cases of Non-Hodgkin’s Lymphoma, 2005 9
2. Number of Agents in Development by Strategy 22


Companies Mentioned Accentia Biopharmaceuticals Amgen Baxter Biogen Idec BioVest International Bristol-Myers Squibb Celgene Cephalon Oncology Chugai EG Labo Eli Lilly Enzon Pharmaceuticals Favrille Fujisawa Deutschland Genentech Genitope Genmab GlaxoSmithKline Gloucester Pharmaceuticals Hana Bioscience Human Genome Sciences Immunomedics Inex Pharmaceuticals Kyowa Large Scale Biologics Merck Millennium Pharmaceuticals Pfizer Roche Seattle Genetics Wyeth


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/362877

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 26/11/2009 12:18:15
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
New Approaches to the Treatment of Non-Hodgkin's Lymphoma
Web Address:
http://www.researchandmarkets.com/reports/362877
Office Code:
OC8HJNMPMSTQQ

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €747.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 26/11/2009 12:18:15

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)